Hypothesis: In seropositive rheumatoid arthritis, a short pulsed senolytic regimen, timed to periods of higher inflammatory burden, will produce a larger reduction in blood epigenetic age acceleration than continuous anti-inflammatory control because selective clearance of senescent synovial and immune cells will restore systemic NAD+ metabolism, improve autophagy flux, and reduce mtDNA-driven inflammaging. Testable prediction: after 12 weeks, participants receiving pulsed senolysis will show lower DNAmGrimAge/PhenoAge acceleration, higher PBMC NAD+/NADH ratio, reduced circulating SASP markers (IL-6, GDF15, CCL2), and improved mitochondrial respiration in isolated T cells versus matched controls, with the strongest effect in those with baseline elevated senescence burden.